Gilbert v. BioPlus Specialty Pharmacy Services, LLC

CourtDistrict Court, M.D. Florida
DecidedSeptember 14, 2023
Docket6:21-cv-02158
StatusUnknown

This text of Gilbert v. BioPlus Specialty Pharmacy Services, LLC (Gilbert v. BioPlus Specialty Pharmacy Services, LLC) is published on Counsel Stack Legal Research, covering District Court, M.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Gilbert v. BioPlus Specialty Pharmacy Services, LLC, (M.D. Fla. 2023).

Opinion

UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF FLORIDA ORLANDO DIVISION

BONNIE GILBERT, DAVID GATZ, WENDY BRYAN, LORI GRADER, DARYL SWANSON, PATRICIA WHITE, ALICIA DUNN, CRYSTAL HULLETT and STEPHEN GABBARD,

Plaintiffs,

v. Case No: 6:21-cv-2158-RBD-DCI

BIOPLUS SPECIALTY PHARMACY SERVICES, LLC,

Defendant.

ORDER This cause comes before the Court for consideration without oral argument on the following motion: MOTION: Plaintiff’s Unopposed Motion for Preliminary Approval of Class Action Settlement (Doc. 68) FILED: July 1, 2023

THEREON it is ORDERED that ruling on the motion is DEFERRED. I. Background In the operative Complaint, the named Plaintiffs bring various claims, including a claim under the Florida Deceptive and Unfair Trade Practices Act (FDUTPA), individually and on behalf of those similarly situated. Doc. 60 (the Complaint). The named Plaintiffs allege that Defendant, a national specialty pharmacy, failed to adequately protect sensitive information including names, dates of birth, addresses, and social security numbers. Id. The named Plaintiffs claim that Defendant experienced a data incident between October 25, 2021 and November 11, 2021, during which an unauthorized third party gained access to its network. Id. (the Data Incident). The parties litigated the case for approximately two years, engaged in discovery, filed dispositive motions, and eventually reached settlement.1 As such, the parties filed a Joint Notice of Settlement, and the Court administratively closed the case and directed the parties to file a

motion for preliminary approval of proposed class settlement. Docs. 64, 65. Pending before the Court is Plaintiffs’ Unopposed Motion for Preliminary Approval of Class Settlement. Doc. 68 (the Motion). For the reasons stated herein, ruling on the Motion is deferred pending additional briefing. A. The Motion On April 26, 2023, the parties filed a Notice of Settlement and stated that they have reached a class-wide settlement. Doc. 64. The named Plaintiffs now move for class certification and preliminary approval of the class action settlement and have attached the Settlement Agreement (the Agreement), notices of settlement to class members, and declarations in support of the request.

Docs. 68; 68-1 to 68-3. The named Plaintiffs certify that Defendant does not oppose the Motion and Defendant has not filed a response and the time for doing so has elapsed. As such, the named Plaintiffs make an unopposed request for the Court to: (1) certify the settlement class pursuant to Federal Rule of Civil Procedure 23(b)(3); (2) preliminarily approve

1 On March 3, 2023, the Court granted in part and denied in part Defendant’s motion to dismiss. Doc. 59. In doing so, the Court permitted the negligence, breach of implied contract, and declaratory judgement claims to proceed without amendment and granted the named Plaintiffs leave to amend their state consumer protection claims. Id. However, the Court dismissed the negligence per se, breach of fiduciary duty, and breach of express contract claims. Id. The named Plaintiffs subsequently filed the Complaint and assert claims for (1) negligence, (2) breach of implied contract, (3) FDUTPA violations, and (4) seek declaratory judgment. Doc. 60. On April 5, 2023, Defendant filed a motion to dismiss the FDUTPA claim but the parties reached settlement before the Court ruled. Docs. 60, 64. the settlement; (3) appoint the proposed class representatives, class counsel, and settlement administrator; (4) approve the notice plan; and (5) approve a schedule leading up to a final approval hearing. B. The Settlement Agreement Plaintiffs propose the following “Settlement Class”:

all persons who were notified that their information may have been impacted in the Data Incident. The Settlement Class specifically excludes: (i) BioPlus and its respective officers and directors; (ii) all Settlement Class Members who timely and validly request exclusion from the Settlement Class; (iii) the Judge and/or magistrate assigned to evaluate the fairness of this settlement; and (iv) any other Person found by a court of competent jurisdiction to be guilty under criminal law of initiating, causing, aiding, or abetting the Data Incident or who pleads nolo contender to any such charge.

Doc. 68-1 at 13. While the Settlement Agreement defines “Settlement Class” in this regard, the named Plaintiffs further divide the class into two groups. Plaintiffs do not call the groups “sub-classes” but in essence the Settlement Agreement provides for two categories of individuals who are treated differently. Plaintiffs identify the first group as “Claims-Made Settlement Class Members” or “Non-SSN Class Members” who include: approximately 218,750 Settlement Class Members who were notified that their information may have been impacted in the Data Incident, and whose Social Security numbers were not impacted in the Data Incident. The Claims-Made Settlement Class Members are eligible to submit a claim under the Claims-Made Benefits.

Id. at 7. A separate settlement fund for this group is described as follows:

The Settlement benefits. . . available to the Claims-Made Settlement Class Members. The Claims-Made Benefits will be funded by BioPlus in an amount not to exceed $1,175,000, inclusive of (i) all Valid Claims for Settlement benefits made under ¶ 2.1; (ii) reasonable Notice and Settlement Administration Costs (defined below) incurred in the administration of both Claims-Made and Common Fund Benefits, including all taxes owed by the Claims-Made Benefits and Common Fund; and (iii) any attorneys’ fees, costs, and expenses, as approved by the Court. Id. at 6-7. The named Plaintiffs explain that through this reversionary fund, Defendant will pay approved fees, costs, and expenses, and from the remaining fund, the Non-SSN Settlement Class Members are permitted to claim (1) compensation of $25 per hour for up to two hours of time spent dealing with issues related to the Data Incident and (2) reimbursement of documented out of pocket expenses or losses up to $750. Id. at 6. Following the payment of attorneys’ fees and expenses, settlement administration expenses, and claims made by Non-SSN Class Members, any funds remaining under the $1,175,000 cap will revert to Defendant. Id. The named Plaintiffs then identify the second group as “Common-Fund Settlement Class Members” or “SSN Class Members” who include:

approximately 130,438 Settlement Class Members who were notified of the Data Incident and who were notified that their Social Security numbers may have been impacted in the Data Incident. Common-Fund Settlement Class Members are eligible to submit a claim under the Common Fund.

Doc. 68-1 at 7-8. The “Common Fund” or “SSN Settlement Fund” is defined as “a non- reversionary common fund to be funded by BioPlus in the amount of $1,025,000.” Id. at 7. Plaintiffs explain that Defendant has agreed to create this non-reversionary fund and SSN Class Members will be able to claim (1) compensation of $25 per hour for up to three hours of time spent dealing with issues related to the Data Incident; (2) reimbursement of documented out of pocket expenses or losses up to $7,500; and (3) a pro rata distribution of funds remaining fund. Doc. 68 at 6. II. Law The Court does not reach the issue of preliminary settlement approval because there are deficiencies with the named Plaintiffs’ request for certification of class for the purpose of settlement. “A class may be certified solely for purposes of settlement where a settlement is reached before a litigated determination of the class certification issue.” Diakos v. HSS Sys., LLC, 137 F. Supp. 3d 1300, 1306 (S.D. Fla.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Henry Lee Pickett v. Iowa Beef Processors
209 F.3d 1276 (Eleventh Circuit, 2000)
Prado-Steiman Ex Rel. Prado v. Bush
221 F.3d 1266 (Eleventh Circuit, 2000)
Valley Drug Co. v. Geneva Pharmaceuticals, Inc.
350 F.3d 1181 (Eleventh Circuit, 2003)
Mills v. Foremost Insurance
511 F.3d 1300 (Eleventh Circuit, 2008)
Amchem Products, Inc. v. Windsor
521 U.S. 591 (Supreme Court, 1997)
Spokeo, Inc. v. Robins
578 U.S. 330 (Supreme Court, 2016)
Geri Siano Carriuolo v. General Motors Company
823 F.3d 977 (Eleventh Circuit, 2016)
Diakos v. HSS Systems, LLC
137 F. Supp. 3d 1300 (S.D. Florida, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
Gilbert v. BioPlus Specialty Pharmacy Services, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/gilbert-v-bioplus-specialty-pharmacy-services-llc-flmd-2023.